Journal of Zhejiang University. Science. B最新文献

{"title":"A method for distinguishing benign and malignant pulmonary nodules based on 3D dual path network aided by <i>K</i>-means clustering analysis.","authors":"Dachuan Gao,&nbsp;Xiaodan Ye,&nbsp;Xuewen Hou,&nbsp;Yang Chen,&nbsp;Xue Kong,&nbsp;Yuanzhong Xie,&nbsp;Shengdong Nie","doi":"10.1631/jzus.B2101009","DOIUrl":"https://doi.org/10.1631/jzus.B2101009","url":null,"abstract":"<p><p>In the USA, there were about 1 ‍806 ‍590 new cancer cases in 2020, and 606 520 cancer deaths are expected to have occurred in 2021. Lung cancer has become the leading cause of death from cancer in both men and women (Siegel et al., 2020). Clinical studies show that the five-year survival rate of lung cancer patients after early diagnosis and treatment intervention can reach 80%, compared with that of patients having advanced lung cancer. Thus, the early diagnosis of lung cancer is a key factor to reduce mortality.</p>","PeriodicalId":17601,"journal":{"name":"Journal of Zhejiang University. Science. B","volume":" ","pages":"957-967"},"PeriodicalIF":0.0,"publicationDate":"2022-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676095/pdf/JZhejiangUnivSciB-23-11-957.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40686682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of regional citrate anticoagulation in patients at high risk of bleeding during intermittent hemodialysis: a prospective multicenter randomized controlled trial.","authors":"Xiaoyan Tang,&nbsp;Dezheng Chen,&nbsp;Ling Zhang,&nbsp;Ping Fu,&nbsp;Yanxia Chen,&nbsp;Zhou Xiao,&nbsp;Xiangcheng Xiao,&nbsp;Weisheng Peng,&nbsp;Li Cheng,&nbsp;Yanmin Zhang,&nbsp;Hongbo Li,&nbsp;Kehui Li,&nbsp;Bizhen Gou,&nbsp;Xin Wu,&nbsp;Qian Yu,&nbsp;Lijun Jian,&nbsp;Zaizhi Zhu,&nbsp;Yu Wen,&nbsp;Cheng Liu,&nbsp;Hen Xue,&nbsp;Hongyu Zhang,&nbsp;Xin He,&nbsp;Bin Yan,&nbsp;Liping Zhong,&nbsp;Bin Huang,&nbsp;Mingying Mao","doi":"10.1631/jzus.B2200082","DOIUrl":"https://doi.org/10.1631/jzus.B2200082","url":null,"abstract":"<p><strong>Objectives: </strong>Safe and effective anticoagulation is essential for hemodialysis patients who are at high risk of bleeding. The purpose of this trial is to evaluate the effectiveness and safety of two-stage regional citrate anticoagulation (RCA) combined with sequential anticoagulation and standard calcium-containing dialysate in intermittent hemodialysis (IHD) treatment.</p><p><strong>Methods: </strong>Patients at high risk of bleeding who underwent IHD from September 2019 to May 2021 were prospectively enrolled in 13 blood purification centers of nephrology departments, and were randomly divided into RCA group and saline flushing group. In the RCA group, 0.04 g/mL sodium citrate was infused from the start of the dialysis line during blood draining and at the venous expansion chamber. The sodium citrate was stopped after 3 h of dialysis, which was changed to sequential dialysis without anticoagulant. The hazard ratios for coagulation were according to baseline.</p><p><strong>Results: </strong>A total of 159 patients and 208 sessions were enrolled, including RCA group (80 patients, 110 sessions) and saline flushing group (79 patients, 98 sessions). The incidence of severe coagulation events of extracorporeal circulation in the RCA group was significantly lower than that in the saline flushing group (3.64% vs. 20.41%, <i>P</i><0.001). The survival time of the filter pipeline in the RCA group was significantly longer than that in the saline flushing group ((238.34±9.33) min vs. (221.73±34.10) min, <i>P</i><0.001). The urea clearance index (<i>Kt</i>/<i>V</i>) in the RCA group was similar to that in the saline flushing group with no statistically significant difference (1.12±0.34 vs. 1.08±0.34, <i>P</i>=0.41).</p><p><strong>Conclusions: </strong>Compared with saline flushing, the two-stage RCA combined with a sequential anticoagulation strategy significantly reduced extracorporeal circulation clotting events and prolonged the dialysis time without serious adverse events.</p>","PeriodicalId":17601,"journal":{"name":"Journal of Zhejiang University. Science. B","volume":" ","pages":"931-942"},"PeriodicalIF":0.0,"publicationDate":"2022-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676090/pdf/JZhejiangUnivSciB-23-11-931.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40686680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma.","authors":"Xiaoyan Yue,&nbsp;Linlin Huang,&nbsp;Yang Yang,&nbsp;Yi Zhao,&nbsp;Donghua He,&nbsp;Xiaoyan Han,&nbsp;Gaofeng Zheng,&nbsp;Yi Li,&nbsp;Enfan Zhang,&nbsp;Zhen Cai,&nbsp;Xin Huang,&nbsp;Jingsong He","doi":"10.1631/jzus.B2200277","DOIUrl":"https://doi.org/10.1631/jzus.B2200277","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a common malignant hematological tumor in adults, which is characterized by clonal malignant proliferation of plasma cells in the bone marrow and secretion of a large number of abnormal monoclonal immunoglobulins (M protein), leading to bone destruction, hypercalcemia, anemia, and renal insufficiency (Alexandrakis et al., 2015; Yang et al., 2018). Since a large number of new drugs, represented by proteasome inhibitors and immunomodulators, have been successfully used to treat MM, treatment efficacy and survival of patients have been significantly improved. However, due to the high heterogeneity of this disease, patients have responded differently to treatments with these new drugs (Palumbo and Anderson, 2011; Wang et al., 2016; Huang et al., 2020). Growth and survival of MM cells depend on the bone marrow microenvironment, especially numerous inflammatory cytokines secreted by myeloma cells and bone marrow stromal cells, such as vascular endothelial growth factor (VEGF), interleukin (IL)‍-6, transforming growth factor-‍β (TGF‍‍-‍‍β), and IL-10. These cytokines can promote the growth of myeloma cells, induce angiogenesis, and inhibit antitumor immunity, and are often linked to patient prognosis (Kumar et al., 2017). In this era of new drugs, the prognostic values of the serum levels of these cytokines in MM need further evaluation.</p>","PeriodicalId":17601,"journal":{"name":"Journal of Zhejiang University. Science. B","volume":" ","pages":"968-974"},"PeriodicalIF":0.0,"publicationDate":"2022-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676094/pdf/JZhejiangUnivSciB-23-11-968.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40703728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in the use of the CRISPR-Cas system for the detection of infectious pathogens.","authors":"Hongdan Gao,&nbsp;Zifang Shang,&nbsp;Siew Yin Chan,&nbsp;Dongli Ma","doi":"10.1631/jzus.B2200068","DOIUrl":"https://doi.org/10.1631/jzus.B2200068","url":null,"abstract":"<p><p>Infectious diseases cause great economic loss and individual and even social anguish. Existing detection methods lack sensitivity and specificity, have a poor turnaround time, and are dependent on expensive equipment. In recent years, the clustered regularly interspaced short palindromic repeats (CRISPR)‍-CRISPR-associated protein (Cas) system has been widely used in the detection of pathogens that cause infectious diseases owing to its high specificity, sensitivity, and speed, and good accessibility. In this review, we discuss the discovery and development of the CRISPR-Cas system, summarize related analysis and interpretation methods, and discuss the existing applications of CRISPR-based detection of infectious pathogens using Cas proteins. We conclude the challenges and prospects of the CRISPR-Cas system in the detection of pathogens.</p>","PeriodicalId":17601,"journal":{"name":"Journal of Zhejiang University. Science. B","volume":" ","pages":"881-898"},"PeriodicalIF":0.0,"publicationDate":"2022-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40686678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and immune response characteristics among vaccinated persons infected with SARS-CoV-2 delta variant: a retrospective study.","authors":"Cunjin Wang, Yong Li, Yuchen Pan, Luojing Zhou, Xi Zhang, Yan Wei, Fang Guo, Yusheng Shu, Ju Gao","doi":"10.1631/jzus.B2200054","DOIUrl":"10.1631/jzus.B2200054","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to observe the clinical and immune response characteristics of vaccinated persons infected with the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Yangzhou, China.</p><p><strong>Methods: </strong>We extracted the medical data of 129 patients with delta-variant infection who were admitted to Northern Jiangsu People's Hospital (Yangzhou, China) between August and September, 2021. The patients were grouped according to the number of vaccine doses received into an unvaccinated group: a one-dose group and a two-dose group. The vaccine used was SARS-CoV-2-inactivated vaccine developed by Sinovac. We retrospectively analyzed the patients' epidemiological, clinical, laboratory, and imaging data.</p><p><strong>Results: </strong>Almost all patients with delta-variant infection in Yangzhou were elderly, and patients with severe/critical illness were over 70 years of age. The rates of severe/critical illness (<i>P</i>=0.006), fever (<i>P</i>=0.025), and dyspnea (<i>P</i>=0.045) were lower in the two-dose group than in the unvaccinated group. Compared to the unvaccinated group, the two-dose group showed significantly higher lymphocyte counts and significantly lower levels of C-reactive protein (CRP), interleukin-6 (IL-6), and D-dimer during hospitalization and a significantly higher positive rate of immunoglobulin G (IgG) antibodies at admission (all <i>P</i><0.05). The cumulative probabilities of hospital discharge and negative virus conversion were also higher in the two-dose group than in the unvaccinated group (<i>P</i><0.05).</p><p><strong>Conclusions: </strong>Two doses of the SARS-CoV-2-inactivated vaccine were highly effective at limiting symptomatic disease and reducing immune response, while a single dose did not seem to be effective.</p>","PeriodicalId":17601,"journal":{"name":"Journal of Zhejiang University. Science. B","volume":" ","pages":"899-914"},"PeriodicalIF":0.0,"publicationDate":"2022-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40686679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron metabolism, ferroptosis, and lncRNA in cancer: knowns and unknowns.","authors":"Lei Qu,&nbsp;Xinyu He,&nbsp;Qian Tang,&nbsp;Xiao Fan,&nbsp;Jian Liu,&nbsp;Aifu Lin","doi":"10.1631/jzus.B2200194","DOIUrl":"https://doi.org/10.1631/jzus.B2200194","url":null,"abstract":"<p><p>Cancer cells undergo substantial metabolic alterations to sustain increased energy supply and uncontrolled proliferation. As an essential trace element, iron is vital for many biological processes. Evidence has revealed that cancer cells deploy various mechanisms to elevate the cellular iron concentration to accelerate proliferation. Ferroptosis, a form of cell death caused by iron-catalyzed excessive peroxidation of polyunsaturated fatty acids (PUFAs), is a promising therapeutic target for therapy-resistant cancers. Previous studies have reported that long noncoding RNA (lncRNA) is a group of critical regulators involved in modulating cell metabolism, proliferation, apoptosis, and ferroptosis. In this review, we summarize the associations among iron metabolism, ferroptosis, and ferroptosis-related lncRNA in tumorigenesis. This information will help deepen understanding of the role of lncRNA in iron metabolism and raise the possibility of targeting lncRNA and ferroptosis in cancer combination therapy.</p>","PeriodicalId":17601,"journal":{"name":"Journal of Zhejiang University. Science. B","volume":"23 10","pages":"844-862"},"PeriodicalIF":0.0,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561407/pdf/JZhejiangUnivSciB-23-10-844.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33528255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UPF1 increases amino acid levels and promotes cell proliferation in lung adenocarcinoma via the eIF2α-ATF4 axis.","authors":"Lei Fang,&nbsp;Huan Qi,&nbsp;Peng Wang,&nbsp;Shiqing Wang,&nbsp;Tianjiao Li,&nbsp;Tian Xia,&nbsp;Hailong Piao,&nbsp;Chundong Gu","doi":"10.1631/jzus.B2200144","DOIUrl":"https://doi.org/10.1631/jzus.B2200144","url":null,"abstract":"<p><p>Up-frameshift 1 (UPF1), as the most critical factor in nonsense-mediated messenger RNA (mRNA) decay (NMD), regulates tumor-associated molecular pathways in many cancers. However, the role of UPF1 in lung adenocarcinoma (LUAD) amino acid metabolism remains largely unknown. In this study, we found that UPF1 was significantly correlated with a portion of amino acid metabolic pathways in LUAD by integrating bioinformatics and metabolomics. We further confirmed that UPF1 knockdown inhibited activating transcription factor 4 (ATF4) and Ser51 phosphorylation of eukaryotic translation initiation factor 2α (eIF2α), the core proteins in amino acid metabolism reprogramming. In addition, UPF1 promotes cell proliferation by increasing the amino-acid levels of LUAD cells, which depends on the function of ATF4. Clinically, UPF1 mRNA expression is abnormal in LUAD tissues, and higher expression of UPF1 and ATF4 was significantly correlated with poor overall survival (OS) in LUAD patients. Our findings reveal that UPF1 is a potential regulator of tumor-associated amino acid metabolism and may be a therapeutic target for LUAD.</p>","PeriodicalId":17601,"journal":{"name":"Journal of Zhejiang University. Science. B","volume":"23 10","pages":"863-875"},"PeriodicalIF":0.0,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561404/pdf/JZhejiangUnivSciB-23-10-863.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33503187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy.","authors":"Delin Kong,&nbsp;Tingting Yang,&nbsp;Jia Geng,&nbsp;Ruirui Jing,&nbsp;Qiqi Zhang,&nbsp;Guoqing Wei,&nbsp;He Huang,&nbsp;Yongxian Hu","doi":"10.1631/jzus.B2200128","DOIUrl":"https://doi.org/10.1631/jzus.B2200128","url":null,"abstract":"<p><p>Despite the advancement of treatments, adults with relapsed/refractory (R/R) B-lineage acute lymphoblastic leukemia (B-ALL) have poor prognosis, with an expected five-year overall survival (OS) rate of 10%‒20% (Nguyen et al., 2008; Oriol et al., 2010). Extramedullary relapse of B-ALL is regarded as a high-risk factor generally associated with poor survival, occurring in about 15% to 20% of all relapsed patients (Ding et al., 2017; Sun et al., 2018). The central nervous system (CNS) and the testes are the most common sites of extramedullary relapse of B-ALL. In addition, extramedullary leukemia can appear in the skin, eyes, breasts, bones, muscles, and abdominal organs. The prognosis of relapsed extramedullary B-ALL after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is extremely poor (Spyridonidis et al., 2012; Dahlberg et al., 2019). Conventional chemotherapy or radiation is often ineffective in such patients. At present, there are no optimal treatment strategies for treating extramedullary leukemia after allo-HSCT.</p>","PeriodicalId":17601,"journal":{"name":"Journal of Zhejiang University. Science. B","volume":"23 10","pages":"876-880"},"PeriodicalIF":0.0,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561409/pdf/JZhejiangUnivSciB-23-10-876.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33503188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer immunotherapy: an evolving paradigm.","authors":"Aifu Lin","doi":"10.1631/jzus.B2210001","DOIUrl":"https://doi.org/10.1631/jzus.B2210001","url":null,"abstract":"<p><p>The inhibition of the host's natural immune response by tumor cells was widely reported in the early phases of the development of oncology therapy, and the concept of employing the host's immune system to treat cancer, i.e. tumor immunotherapy, is not new. However, as a result of early theoretical constraints, clinical application of immunotherapy did not go smoothly and lagged significantly behind radiation and chemotherapy. The path has been winding, but the future now seems promising. Immunotherapy research has advanced enormously as a result of the maturing of immuno-editing theory and the creation of numerous technologies, despite a number of unsuccessful endeavors and clinical studies. Since around 1998, the US Food and Drug Administration (FDA) has approved a variety of tumor immunotherapies, including cytokines (interleukin-2, interferons), cancer vaccines (Provenge), immune checkpoint inhibitors (ipilimumab), and cellular therapies (chimeric antigen receptor-T (CAR-T)), signaling a boom in the field.</p>","PeriodicalId":17601,"journal":{"name":"Journal of Zhejiang University. Science. B","volume":"23 10","pages":"791-792"},"PeriodicalIF":0.0,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561410/pdf/JZhejiangUnivSciB-23-10-791.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33503183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor-infiltrating immunocytes.","authors":"Jing Chen,&nbsp;Jian Chen,&nbsp;Lie Wang","doi":"10.1631/jzus.B2200174","DOIUrl":"https://doi.org/10.1631/jzus.B2200174","url":null,"abstract":"<p><p>Tertiary lymphoid structures (TLSs) are formations at sites with persistent inflammatory stimulation, including tumors. These ectopic lymphoid organs mainly consist of chemo-attracting B cells, T cells, and supporting dendritic cells (DCs). Mature TLSs exhibit functional organization for the optimal development and collaboration of adaptive immune response, delivering an augmented effect on the tumor microenvironment (TME). The description of the positive correlation between TLSs and tumor prognosis is reliable only under a certain condition involving the localization and maturation of TLSs. Emerging evidence suggests that underlying mechanisms of the anti-tumor effect of TLSs pave the way for novel immunotherapies. Several approaches have been developed to take advantage of intratumoral TLSs, either by combining it with therapeutic agents or by inducing the neogenesis of TLSs.</p>","PeriodicalId":17601,"journal":{"name":"Journal of Zhejiang University. Science. B","volume":"23 10","pages":"812-822"},"PeriodicalIF":0.0,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561406/pdf/JZhejiangUnivSciB-23-10-812.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33503185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}